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Type 1 diabetes (T1D) results from the progressive loss of β cells, a process propagated by pro-
inflammatory cytokine signaling that disrupts the balance between pro- and anti-apoptotic 
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proteins. To identify proteins involved in this process, we performed comprehensive proteomics of 
human pancreatic islets treated with interleukin-1β and interferon-γ, leading to the identification 
of 11,324 proteins, of which 387 were significantly regulated by treatment. We then tested the 
function of growth/differentiation factor 15 (GDF15), which was repressed by the treatment. We 
found that GDF15 translation was blocked during inflammation, and it was depleted in islets from 
individuals with T1D. The addition of exogenous GDF15 inhibited interleukin-1β+interferon-γ-
induced apoptosis of human islets. Administration of GDF15 reduced by 53% the incidence of 
diabetes in NOD mice. Our approach provides a unique resource for the identification of the 




Nakayasu et al. used a proteomics-based approach in human islets to study the T1D-related 
process of β-cell destruction. They found that pro-inflammatory cytokines lead to the suppression 
of GDF15 mRNA translation. The study also revealed that GDF15 promotes the protection of β 
cells and prevents diabetes onset in mice.
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Type 1 diabetes (T1D) is a chronic disease that affects approximately 1.25 million people in 
the U.S. Insulin administration successfully ameliorates the symptoms of T1D, but it does 
not prevent or cure this devastating disease, which shortens the lifespan of those affected by 
more than 10 years (Atkinson et al., 2014; DiMeglio et al., 2018; Livingstone et al., 2015). 
Since T1D is caused by a gradual, autoimmune-mediated destruction of insulin-producing β 
cells in the pancreatic islet, immunotherapies have been extensively tested to prevent or 
arrest disease (Ehlers, 2016). Recent clinical trial efforts suggest that immunomodulation 
can delay disease onset in certain-high risk individuals, but responses to drug therapy are 
typically heterogeneous and limited in duration (Herold et al., 2019). A major hurdle in this 
process is a lack of understanding around the response of pancreatic β cells during immune 
activation and disease evolution.
Pro-inflammatory cytokines, such as interferon (IFN)-γ, interleukin (IL)-1β, and tumor 
necrosis factor (TNF)-α, can be potent mediators of β-cell destruction by amplifying cell-
mediated inflammation, directly activating apoptotic signaling, and inducing pro-apoptotic 
proteins (Eizirik et al., 2009; Eizirik et al., 2012; Ramos-Rodríguez et al., 2019). In addition, 
these cytokines have been shown to contribute to apoptosis by inducing mitochondrial 
dysfunction and endoplasmic reticulum stress (Eizirik et al., 2013; Gurzov and Eizirik, 
2011). To prevent massive tissue damage, the organism has feedback mechanisms that 
counterbalance the effects of the pro-inflammatory cytokines (Elenkov and Chrousos, 2002). 
These feedback mechanisms, however, seem to be altered in T1D, failing to prevent a strong 
and progressive decrease in the β-cell population (Campbell-Thompson et al., 2016; Gupta 
et al., 2014). We hypothesized that comprehensive proteomics analyses of the cytokine 
responses in human islets could identify key pathways in the β cell that are up- or 
downregulated, which could define new targets that could be exploited for the development 
of T1D therapies.
Using comprehensive proteomics analysis, we aimed to unveil the molecular signatures of 
cytokine-induced β cell signaling to identify factors that regulate the balance between cell 
death and survival. Human pancreatic islets were treated with a combination of the pro-
inflammatory cytokines, IL-1β and IFN-γ, and submitted to an in-depth proteomic analysis, 
leading to the identification and quantification of approximately 11,000 proteins. Our data 
showed significant activation of pathways related to inflammation, antigen processing and 
presentation, apoptosis, and cytokine signaling. Based on these expression profiles, we 
identified and confirmed growth/differentiation factor 15 (GDF15, also known as 
macrophage inhibitory cytokine 1 [MIC-1]) as an islet-protective factor. This study 
exemplifies the utility of advanced proteomics to elucidate signaling pathways and identify 
interesting factors or targets for mechanistic study and elucidates the mechanism of GDF15 
synthesis regulation by pro-inflammatory cytokines, its function in blocking apoptotic 
signaling, and in vivo activity in preventing insulitis.
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Comprehensive Proteomic Analysis of Human Pancreatic Islets Treated with Cytokines
To investigate the molecular responses to pro-inflammatory stress that lead to β-cell death, 
human pancreatic islets from each of 10 non-diabetic cadaveric donors were treated with or 
without 50 U/mL IL-1β + 1,000 U/mL IFN-γ for 24 h. Due to the limited number of 
channels in the tandem-mass tags (TMT) kit used, islet samples from 5 different donors, 
including the samples treated with cytokines and respective controls, were combined in one 
TMT set, whereas the samples from the other 5 donors were multiplexed in a second set. 
Each TMT set was fractionated by high-pH reversed-phase chromatography and analyzed by 
liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) (Figure 1A) (Pride 
repository: PXD009131). The proteomic analysis resulted in the identification and 
quantification of 11,324 proteins, of which 9,695 proteins were identified in both TMT 
experiments (Table S1; Figure 1B). A total of 387 of these proteins were consistently and 
significantly altered in abundance in response to the cytokine treatment in both TMT sets 
(Table S2; Figure 1C). To ensure the biological significance of the data, we performed a post 
hoc statistical power analysis. The average power with a paired sample size of 5 was 0.93 for 
both sets 1 and 2. Evaluating each protein for adequate power indicated that 87.7% of 
proteins in both sets had a power of great than 0.8 to detect a fold change of 1.5 for sets 1 
and 2, respectively. (Figures S1A and S1B). The power analysis confirmed that the size of 
the present study is appropriate to investigate even small changes in protein abundances in 
response to the cytokine treatment.
Multiplexing samples using TMT combined with extensive fractionation of peptides prior to 
LC-MS/MS analysis leads to comprehensive coverage of the proteome; however, it may also 
result in protein fold change compression (Ow et al., 2009). Therefore, to more accurately 
determine the extent of fold changes in protein abundances, we performed an independent, 
label-free proteomics analysis of islets from two additional donors. These samples had the 
same cytokine treatment and were digested with trypsin before being analyzed by a label-
free 2D LC-MS/MS proteomic approach (Figure S2C). Proteins such as E3 ubiquitin-protein 
ligase RNF213, fractalkine, and ubiquitin D had only modest (1.7 to 2.9) fold change 
(comparing the signal intensities of treated versus control samples) in the TMT-labeled 
experiment. However, in the label-free analysis, this difference was much larger (E3 
ubiquitin-protein ligase RNF213, fractalkine, and ubiquitin D were only detected in samples 
after treatment) (Figure S2D), showing that the extent of regulation in protein expression is 
higher than detected in the TMT-labeled experiment. Notably, and despite the fold change 
compression, these proteins were correctly identified as regulated by the cytokine treatment.
The label-free proteomics experiment also served to validate the overall findings from the 
TMT-labeled analysis, since it was based on an independent experiment, i.e., the islets were 
obtained from two additional non-diabetic donors and treated with cytokines in a different 
laboratory using the same protocol. Furthermore, the samples were analyzed using an 
alternative proteomics pipeline without TMT labeling and an independent label-free 
quantification approach. In the label-free proteomics dataset, a total of 6,038 proteins were 
identified, including 207 of the 387 significantly regulated proteins found in the TMT-
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labeled proteomics experiment. Out of these 207 proteins, 182 (88%) were regulated in the 
same direction compared to proteins identified in the TMT-labeled proteomics experiment 
(Figures S2D and S2E). Overall, this independent analysis cross-validated a large portion of 
the proteins found to be significantly regulated by the IL-1β + IFN-γ treatment and showed 
that some of the proteins found to be differentially expressed in the first experiment were 
even more markedly modified than initially assumed.
Cellular Pathways Regulated by the IL-1β + IFN-γ Treatment
We next performed a function-enrichment analysis using the DAVID database to determine 
pathways regulated by the cytokine treatment. A total of 49 pathways were significantly 
enriched with cytokine-regulated proteins (Figure 1D). To facilitate interpretation, we 
clustered different pathways into main biological processes based on their overlapping 
signaling (shared proteins) as previously described (Merico et al., 2010). The analysis 
revealed that the cytokine treatment regulated proteins related to NF-κB signaling, cytokine-
cytokine receptor interactions, apoptosis, antigen processing and presentation, extracellular 
matrix, coagulation and complement cascades, rheumatoid arthritis, and transcriptional mis-
regulation in cancer (Figure 1D). Because β-cell death was the main phenotype of interest in 
our study, we next performed a more detailed analysis of proteins related to apoptosis using 
the MetaCore tool, which led to the assignment of 88 differentially abundant proteins to this 
function, of which 73 (83%) were annotated to be physically or functionally interacting with 
each other (Figure S1F). Of note, most of the proteins in this pathway were upregulated with 
the treatment, while some potential inhibitors of apoptosis, such as thrombospondin 1 
(Cunha et al., 2017), were downregulated. This observation supports the hypothesis that pro-
inflammatory cytokines induce cell death by breaking the homeostatic balance between pro- 
and anti-apoptotic factors.
Another pathway that drew our attention was the cytokine-cytokine receptor interaction 
because this indicated that the IL-1β + IFN-γ treatment regulates the expression of 
cytokines and receptors that might result in sequential, feedforward signaling events in the 
cells. Importantly, these types of molecules are pharmacologically active, making them 
potential candidates for therapies. The present proteomics analysis detected and identified 54 
cytokines, chemokines, and growth factors, of which 19 were regulated by IL-1β + IFN-γ. 
Out of these regulated cytokines, chemokines, and growth factors, 16 were upregulated, 
while only 3 were downregulated (Figure 2A). Taken together, the proteomic analysis 
showed a significant regulation of proteins related to cytokine signaling and apoptosis in 
pancreatic islets treated with pro-inflammatory cytokines.
Abundance Profiles of Selected Proteins in Cells and In Vivo
To identify possible therapeutic targets, we prioritized proteins to be further studied based on 
four criteria: (1) regulation in response to the IL-1β + IFN-γ treatment, (2) function in 
apoptosis, (3) classification as cytokines, chemokines, or growth factors, and (4) validation 
by the label-free proteomic analysis. Only 5 proteins matched all these criteria: fractalkine, 
IL-1α, IL-1β, osteopontin (secreted phosphoprotein 1 [SPP1]), and growth/differentiation 
factor 15 (GDF15). Of those cytokines, SPP1 and GDF15 were chosen for further study 
because there was limited information about their role in T1D, yet they have been described 
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as regulating different aspects of the immune response (Artz et al., 2016; Bootcov et al., 
1997; Cai et al., 2018; Clemente et al., 2016; Kahles et al., 2014). We first validated 
cytokine-mediated downregulation of SPP1 and GDF15 by treating the EndoC-βH1 human 
β-cell line and the mouse MIN6 β-cell line with IL-1β + IFN-γ. Immunoblot analysis 
confirmed the reduction in SPP1 and GDF15 protein expression in response to cytokine 
treatment by 25% and 35%, respectively, in EndoC-βH1 cells (Figure 2B). Similar results 
were observed in MIN6 cells (Figure 2C). We next analyzed the expression of GDF15 and 
SPP1 in vivo in mouse islets from non-obese diabetic (NOD) mice, a model of autoimmune 
diabetes (Makino et al., 1980). Pancreata from 8-week-old normoglycemic female NOD 
mice with or without insulitis were analyzed by immunofluorescence using antibodies 
against GDF15 and SPP1. There was a decreased abundance of GDF15 and SPP1 in islets 
from NOD mice with insulitis compared to those from NOD mice without insulitis (Figures 
2D and 2E). Taken together, these results suggest that several pathways, including cytokine-
receptor interaction, antigen presentation, and apoptosis, are regulated by the IL-1β + IFN-γ 
treatment in human islets. The results also demonstrated a downregulation of GDF15 and 
SPP1 in β cells, a finding that was also observed in murine islets with insulitis in vivo.
Mechanism Regulating GDF15 and SPP1 Expression in Human Islets
Pro-inflammatory cytokines can regulate the levels of proteins by a variety of mechanisms, 
ranging from transcription and translation to protein degradation and secretion (Carpenter et 
al., 2014). To investigate possible regulatory mechanisms, we compared the protein and 
transcript levels of GDF15 and SPP1 in human islets treated with IL-1β + IFN-γ. Both 
proteins were significantly reduced in response to cytokine treatment: GDF15 was 
downregulated by 70%, and SPP1 was reduced by approximately 60% (Figure 3A). These 
data were confirmed by immunoblot analysis, which showed a reduction of approximately 
20% and 60% in the levels of SPP1 and GDF15, respectively (Figures 3A and S2). 
Consistent with a likely transcriptional mechanism of regulation, levels of the mRNA 
encoding SPP1 were coordinately decreased by about 70% by cytokine treatment (Figure 
3A). By contrast, levels of the mRNA encoding GDF15 were increased two-fold by cytokine 
treatment, suggesting a regulation of this protein at the post-transcriptional level. We then 
investigated whether this phenomenon was restricted to GDF15 by comparing the expression 
of the 387 proteins regulated by IL-1β + IFN-γ to their corresponding mRNA levels from a 
transcriptomics analysis of human islets exposed to the same cytokines (Eizirik et al., 2012). 
Among the proteins whose expression increased following cytokine treatment, 65% showed 
a synchronized increase in their corresponding mRNAs (Figure 3B). In contrast, only 35% 
of the downregulated proteins showed a significant decrease in their transcript levels (Figure 
3B). Together, these data suggest that decreases in protein abundance are more likely to be 
independent of reduction in transcriptional rates, whereas increases in protein expression 
correspond to coordinate increases in mRNAs.
Several posttranscriptional mechanisms might account for regulation of protein levels, 
including alterations at the level of ribosome engagement during mRNA translation, for 
instance, secondary to ER stress (Carpenter et al., 2014). To test whether the decrease in 
GDF15 protein level during cytokine treatment was due to a block in GDF15 mRNA 
translation, we performed polyribosomal profiling experiments (Templin et al., 2014). 
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Results from polyribosomal profiling showed that during cytokine treatment, GDF15 mRNA 
was found mostly in the monoribosomal fractions, as measured by qPCR (Figures 3C and 
3D). These results indicate that GDF15 mRNA translation is blocked by treatment with pro-
inflammatory cytokines.
GDF15 Protects β Cells from IL-1β- and IFN-γ-Induced Cell Death
As shown in Figure S2, not all proteins in the apoptotic pathway were upregulated with the 
cytokine treatment. We hypothesized that downregulated proteins in this pathway could be 
anti-apoptotic factors, since the treatment induces cell death. To test this hypothesis, we first 
performed a network analysis with the Metacore tool of the downstream signaling regulated 
by GDF15 and SPP1. This analysis showed some overlap on the signaling transduction 
pathways, with both GDF15 and SPP1 signaling converging to regulating apoptosis (Figure 
4A), thereby indicating their potential on regulating cell death. We then pre-treated the 
human insulin-producing EndoC-βH1 cells with 50 ng/mL of recombinant SPP1 (rSPP1) or 
100 ng/mL of recombinant GDF15 (rGDF15) for 12–16 h followed by treating with IFN-γ + 
IL-1β for another 24 h. Apoptosis was assessed by western blot analysis of cleaved caspase 
3. As expected, IFN-γ + IL-1β treatment alone induced apoptosis as indicated by 3-fold 
increase in the amount of cleaved caspase 3 (Figures 4B–4D). Pretreatment with GDF15 and 
SPP1, however, led to an ~50% reduction in cleaved caspase 3 (Figures 4B–4D). We 
performed similar treatment of human islets and measured caspase 3/7 activity by a 
luminescence assay, which confirmed a complete protection by rGDF15 and rSPP1 pre-
treatment against cytokine-induced apoptosis (Figure 4E). Additionally, viability and 
apoptosis studies on human islets performed using flow cytometry showed similar beneficial 
effects of rGDF15 and rSPP1 against cytokines (Figure S3). Therefore, we conclude that 
GDF15 and SPP1 protect EndoC-βH1 cells and human islets from apoptosis induced by 
exposure to IFN-γ + IL-1β.
GDF15 Inhibits Insulitis and Decreases Incidence of Diabetes in NOD Mice
After determining that GDF15 protected β cells from IFN-γ + IL-1β-induced apoptosis, we 
addressed the question of whether it could also protect pancreatic islets in vivo. Therefore, 
we treated 6-week-old female NOD mice (n = 5) every two days for two weeks with 
rGDF15 or vehicle alone. The body weight and blood glucose levels were monitored over 
the treatment period and were shown to be stable and unaffected by the GDF15 
administration (Figures 5A and 5B), which is expected since at this stage, NOD mice are not 
yet hyperglycemic. After the treatment period, mice were euthanized and pancreata were 
excised for histopathological analysis. This analysis showed a significant decrease in 
insulitis of GDF15-treated mice compared to the control group (Figures 5C and 5D). The 
decrease in insulitis was accompanied by a reduction in oxidative stress, as shown by 
immunostaining of the lipid peroxidation marker, 4-hydroxynonenal (4HNE) (Figure 5E). 
Having shown that GDF15 reduced insulitis, we hypothesized that it could also prevent or 
delay the incidence of diabetes. To test this hypothesis, 6-week-old NOD mice (n = 20) were 
treated with rGDF15 every 2 days for 4 weeks and monitored for up to 24 weeks of age for 
the development of diabetes (defined as blood glucose > 250 mg/dL on two consecutive 
measurements). GDF15 treatment reduced by 53% (p = 0.006) the incidence of diabetes in 
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these mice (Figure 6). Overall, these data show a reduction in insulitis and oxidative stress 
by GDF15 in vivo, leading to reduced incidence of diabetes in NOD mice.
GDF15 Levels in Pancreatic Sections of Individuals with Diabetes
Finally, to validate our findings from in vitro and in vivo models in human T1D, we 
investigated the levels of GDF15 in pancreas from donors with diabetes. The 
immunostaining analysis showed that GDF15 was present in different parts of the pancreas 
but with relatively higher abundance in islets (Figure 7A, row 1). Islets from donors with 
T1D exhibited an ~10-fold reduction in GDF15 abundance (Figures 7A, rows 2 and 3, and 
7B). Two of the donors with T1D had residual insulin abundance and decreased but still 
detectable levels of GDF15 (Figures 7A, row 3, and 7B). On the other hand, islets from 
individuals with T2D and from individuals with no diabetes had similar abundance of 
GDF15 (Figures 7A, row 4, and 7B). For comparison, no significant changes in the levels of 
glucagon abundance were observed in islets from donors with T1D or T2D compared to the 
control group. Taken together, our data showed that the abundance of GDF15 is reduced in 
islets of individuals with T1D, similar to what we found with islets treated with pro-
inflammatory cytokines and in islets from NOD mice with insulitis.
DISCUSSION
In this paper, we aimed to the test the balance between pro- and anti-apoptotic signaling 
induced by cytokines in the context of β-cell death by performing a comprehensive 
proteomics analysis of cytokine-treated islets. In our study, we leveraged recent advances in 
mass spectrometry-based proteomics to enable the detection of many extremely low 
abundance proteins, such as cytokines, chemokines, and growth factors, providing a more 
complete picture of the pathways regulated by pro-inflammatory cytokines in human islets. 
This deep proteomics coverage resulted in the precise identification and quantification of 
over 11,000 proteins in human islets. Overall, the treatment revealed a strong regulation of 
pathways such NF-κB signaling, cytokine-cytokine receptor interaction, apoptosis, and 
antigen processing and presentation. Supporting the hypothesis that β cells die due to an 
imbalance between pro- and anti-apoptotic factors, well-described apoptotic activators, such 
as PTPN2 and STAT1 (Santin et al., 2011; Suk et al., 2001), were upregulated with the 
treatment, whereas SPP1 and connective tissue growth factor (CTGF), proteins described to 
protect and regenerate β cells, respectively (Guney et al., 2011; Lyssenko et al., 2011), were 
downregulated after the IFN-γ + IL-1β treatment.
To further investigate the balance between pro- and anti-apoptotic factors, we next studied 
the mechanism of GDF15 downregulation due to IFN-γ + IL-1β treatment, since GDF15 
had previously been shown to inhibit apoptosis in endothelial cells (Li et al., 2013). We 
showed that GDF15 abundance was reduced in cytokine-treated human islets and in human 
and rodent β cell lines by translational blockade. This phenomenon seems to be extensive 
and not restricted to GDF15, since only 35% of the downregulated proteins were regulated at 
the transcriptional level. In terms of GDF15 regulation, this gene is post-transcriptionally 
regulated in murine macrophages by tristetraprolin (TTP or ZFP36), an RNA-binding 
protein that targets transcripts containing adenylate-uridylate (AU)-rich elements (AREs) for 
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degradation (Tiedje et al., 2016). TTP is indeed a major regulator of the inflammatory 
response by targeting cytokine mRNAs to degradation, as these transcripts often bear AREs 
(Sedlyarov et al., 2016). TTP has also been shown to bind and prevent specific transcripts to 
be translated (Brooks and Blackshear, 2013), but its role in regulating GDF15 levels in the 
islets requires further investigation. Of note, TTP mRNA expression is increased by >2-fold 
(p < 0.05) following IFN-γ + IL-1β treatment of human islets, as evaluated by RNA 
sequencing of two different batches of human islet preparations (n = 5 each) (Eizirik et al., 
2012; Gonzalez-Duque et al., 2018).
We next showed that GDF15 inhibited cytokine-induced apoptosis of human islets and a β-
cell line. GDF15 was first reported to act as an anti-inflammatory cytokine that decreases the 
production of TNF-a in macrophages activated with bacterial lipopolysaccharide (Bootcov et 
al., 1997). The anti-apoptotic property of GDF15 is not surprising, since it inhibits 
inflammation, a process that often triggers apoptosis. Indeed, anti-apoptotic effects of 
GDF15 have been documented in other tissues (Heger et al., 2010; Schiegnitz et al., 2012), 
but they have not been studied in islets yet. In terms of signaling, the GDF15 receptor was 
recently identified to be GDNF family receptor α-like (GFRAL), which requires co-receptor 
RET to elicit intracellular signaling (Emmerson et al., 2017; Hsu et al., 2017; Mullican et al., 
2017; Yang et al., 2017). Despite the deep coverage of our proteomic analysis, GFRAL and 
RET proteins were not detected, which indicates that these proteins might be expressed at 
very low levels. There is also a possibility that GDF15 interacts with a different receptor or 
that it inhibits pro-apoptotic signaling by other mechanisms. For instance, Luan et al. 
showed that GDF15 induces immune tolerance in acute infections and sepsis through 
mobilization of triacylglycerols from the liver, which reduces inflammation systemically 
(Luan et al., 2019). GDF15 has also been shown to inhibit angiogenesis by interacting and 
blocking CTGF signaling (Whitson et al., 2013). Interestingly, GDF15 and CTGF have been 
shown to be co-regulated in cardiac fibrosis and jejunum damage (Krusche et al., 2011; Yu 
et al., 2010), which was also observed in human islets treated with IL-1β + IFN-γ (Figure 
2A). However, the role of this co-regulation in preventing β-cell apoptosis remains to be 
clarified.
GDF15 has been associated with a variety of metabolic syndrome-related diseases, such as 
cardiovascular diseases, obesity, and type 2 diabetes (Unsicker et al., 2013), and is a marker 
of myocardial infarction and a prognostic factor of heart failure (Khan et al., 2009). 
Increased levels of GDF15, however, do not seem to be a causative factor for heart failure 
but rather a consequence of the cellular responses aimed at repairing damaged heart muscle 
(Kempf et al., 2011). Indeed, molecular studies have shown that GDF15 protects the heart 
from fatal rupture after myocardial infarction (Kempf et al., 2011). In obesity, GDF15 was 
first associated with anorexia-cachexia of cancer patients, likely as the consequence of 
overexpression of this protein by tumor or tumor-associated immune cells (Tsai et al., 2016), 
observations that were fundamental for the discovery of its functions in controlling body 
weight. High levels of GDF15 activate the GFRAL receptor in the hindbrain, reducing 
appetite and food intake and promoting weight loss (Chung et al., 2017; Emmerson et al., 
2017; Hsu et al., 2017; Mullican et al., 2017; Yang et al., 2017). In addition, GDF15 was 
shown to be an important signal in response to nutrition stress induced by long-term high-fat 
feeding or dietary amino acid imbalance (Patel et al., 2019). In diabetes, increased levels of 
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GDF15 are present in the plasma of individuals with T2D, but this phenomenon seems to be 
independent of the incidence of the disease (Carstensen et al., 2010). Moreover, GDF15 
improves insulin sensitivity in mice fed a high-fat chow (Chung et al., 2017; Jung et al., 
2018; Lee et al., 2017), showing its potential for treating T2D. Our data add another element 
to this growing literature; namely, it indicates a directly protective effect of GDF15 against 
cytokine-induced β-cell apoptosis. This protection was also observed in vivo, as GDF15 
administration reduced by 53% the incidence of diabetes in NOD mice. Although it is 
difficult to make a direct comparison due to differences in the treatment regimens, similar 
levels of protection were observed for anti-CD3, ω−3 fatty acid, and palmitic acid esters of 
hydroxy stearic acid treatments (Bi et al., 2017; Bresson et al., 2006; Syed et al., 2019).
In conclusion, we present a unique resource for the identification of human islet proteins 
regulated by pro-inflammatory cytokines. By mining this new dataset, and integrating it with 
available RNA sequencing data, we detected an imbalance between pro- and anti-apoptotic 
proteins modulated by IL-1 + IFN-γ in β cells. This imbalance includes a post-
transcriptional downregulation of GDF15, presently shown to act as an anti-apoptotic 
protein. This finding provides a proof of concept for the utility of the present resource. 
Additional extension and mining of the human islet proteome has the potential to indicate 
novel avenues for the therapy of diabetes.
Limitations of Study
Here, we have shown that GDF15 can prevent IL-1β + IFN-γ-induced apoptosis in human 
islets and EndoC-βH1 cells. We also showed that it can inhibit insulitis and partially prevent 
diabetes in NOD mice. However, a limitation of the study is the lack of understanding of the 
GDF15 mechanism of action. We showed that GDF15 has effects directly in human islets 
and EndoC-βH1 cells, but its receptor, GFRAL, is currently thought to be only expressed in 
the hindbrain (Emmerson et al., 2017; Hsu et al., 2017; Mullican et al., 2017; Yang et al., 
2017). Therefore, additional work needs to be done to determine whether GDF15 has a 
receptor in human islets or if it acts through a systemic action of the hindbrain.
STAR★METHODS
LEAD CONTACT AND MATERIALS AVAILABILITY
Requests for further information and resources should be directed to and will be fulfilled by 
the Lead Contact, Thomas Metz (thomas.metz@pnnl.gov). Proteomics data are available as 
described below. No other reagents or resources were generated as a part of this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Islets—Pancreatic islets from cadaveric donors were acquired from the Integrated 
Islet Distribution Program (IIDP) (Brissova et al., 2019). Because the tissues came from 
cadaveric donors, the study was not considered human subjects research, and no consent was 
required.
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The characteristics of the tissue donors are listed in Table S3. The mean and standard 
deviation in age of the donors was 44.1 ± 12.8 years. The mean and standard deviation in 
BMI of the donors was 28.9 ± 5.1. Islets were obtained from 15 males and 12 females.
To ensure the biological significance of the data we performed a post hoc statistical power 
analysis. The average power with a paired sample size of 5 was 0.93 for both proteomics sets 
1 and 2. Evaluating each protein for adequate power indicated that 87.7% of proteins in both 
sets had a power of greater than 0.8 to detect a fold-change of 1.5 for sets 1 and 2, 
respectively. (Figures S1A and S1B). The power analysis confirmed that the size of the 
present study is appropriate to investigate even small changes in protein abundances in 
response to the cytokine treatment.
An analysis of the influence of sex on the results of the study was not performed, since there 
was not adequate power in the study to address this question.
Human islets were received from IIDP as described above and were required to have a 
minimum of 85% purity as measured by dithizone and 90% viability. Islets were maintained 
in Standard Islet Medium (Prodo) supplemented with human AB serum (Prodo), 
Ciprofloxacin (Fisher) and glutamine and glutathione (Prodo) at 37°C, under 100% humidity 
and 5% CO2 atmosphere. To study the protective effect of GDF15 and SPP1, we pretreated 
islets with human recombinant 100 ng/mL GDF15 (Sino Biologicals) and 50 ng/mL SPP1 
(GenTex), followed by cytokine treatment for 24 h. Recombinant GDF15 was previously 
tested for TGF-β contamination by ELISA, confirming absence of TGF-β in the sample.
EndoC-βH1 Human β Cell Line—EndoC-βH1 is a male, engineered cell line resulted 
from the lentiviral transfection of SV40LT expressed under the control of the insulin 
promoter (Ravassard et al., 2011). This cell line has been shown to respond to glucose 
stimulus by secreting insulin and it serves as an adequate model for studying cytokine-
mediated β cell death (Gurgul-Convey et al., 2015; Gurgul-Convey et al., 2016).
EndoC-βH1 cells were obtained from Dr. R. Scharfmann (University of Paris, France) and 
cultured as described previously (Scharfmann et al., 2014). Briefly, EndoC-βH1 cells were 
maintained at 37°C and 5% CO2 atmosphere, and in DMEM media consisting of 1 g/L each 
of D-glucose and L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, 2% 
albumin from bovine fraction V, 50 μM 2-mercaptoethanol, 10 mM nicotinamide, 5.5 μg/ml 
transferrin, and 6.7 ng/mL sodium selenite. To study the protective effect of GDF15 and 
SPP1, we pretreated EndoC βH1 cells and human islets with human recombinant 100 ng/mL 
GDF15 (Sino Biologicals) and 50 ng/mL SPP1 (GenTex), followed by cytokine treatment 
for 24 h. Recombinant GDF15 was previously tested for TGF-β contamination by ELISA, 
confirming absence of TGF-β in the sample.
MIN6 Murine β Cell Line—MIN6 is a male, insulinoma-derived cell line from transgenic 
mice transfected with SV40 T-antigen that has the ability to secrete insulin on the presence 
of glucose (Ishihara et al., 1993).
MIN6 cells were maintained under standard culture conditions (Miyazaki et al., 1990). 
Briefly, MIN6 cells were maintained at 37°C and 5% CO2 atmosphere, and in DMEM media 
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consisting of 4.5 g/L each of D-glucose and L-glutamine, 10% fetal bovine serum, 100 
units/mL penicillin, 100 μg/mL streptomycin, 20 mM HEPES, and 50 mM 2-
mercaptoethanol.
Mice—5-week-old female NOD/ShiLTJ (NOD) mice were purchased from Jackson 
Laboratories and maintained as per the approved protocol from Indiana University Animal 
Care and Use Committee. Mice were housed in a standard 12 h light:dark cycle 
(6:00am-6:00pm) with a temperature range between 18–23°C. Mice were fed a standard 
chow diet (2018S, Harlan Laboratories). Health status was checked daily by veterinary 
technicians.
NOD mice spontaneously develop autoimmune diabetes with many similarities to human 
T1D, such as pancreas autoantibodies and autoreactive CD4+ and CD8+ T lymphocytes 
(Anderson and Bluestone, 2005).
Human Pancreas—Histological slices of human pancreata from cadaveric donors were 
kindly provided by the Network for Pancreatic Organ Donors with Diabetes (nPOD) 
(Pugliese et al., 2014). Because the tissues came from cadaveric donors, the study was not 
considered human subjects research, and no consent was required.
The characteristics of the tissue donors are listed in Table S4. The mean and standard 
deviation in age of the donors was 39.3 ± 9.9 years for control individuals (n = 3 male and 5 
female), 32.9 ± 5.3 for type 1 diabetic individuals (n = 4 male and 6 female), and 45.6 ± 8.1 
for type 2 diabetic individuals (n = 2 male and 2 female). The mean and standard deviation 
in BMI of the donors was 26.5 ± 5.3 for control individuals, 25.5 ± 3.9 for type 1 diabetic 
individuals, and 34.6 ± 6.7 for type 2 diabetic individuals.
An analysis of the influence of sex on the results of the study was not performed.
METHOD DETAILS
Pancreatic Islet Culture and Treatment—The islet cultures were cultured as described 
above, left to recover overnight and then treated with cytokines by adding fresh medium 
containing 50 U/mL IL-1β and 1000 U/mL IFN-γ, or left untreated by adding fresh medium 
without cytokines, and cultured for 24 h. Treated islets were collected into microcentrifuge 
tubes and washed twice by adding PBS containing 1% phosphatase inhibitor cocktail 
(Thermo Fisher Scientific) and 10 mM NaF (Sigma Aldrich), spinning at 1200 rpm at 4°C 
for 2 min and discarding the supernatant. Samples were then flash frozen with liquid N2 and 
stored at −80°C before processing.
Proteomic Analysis Using Tandem Mass Tags—Samples were submitted to 
Metabolite, Protein and Lipid Extraction (MPLEx), as previously described (Nakayasu et al., 
2016). Briefly, 300–500 treated or control islets from the same 10 donors were resuspended 
in milliQ water, and 5 volumes of 2:1 (v:v) chloroform:-methanol solution was added. The 
samples were then incubated on ice for 5 min, vigorously vortexed for 1 min and centrifuged 
at 12,000 rpm at 4°C for 10 min. The protein disk was collected and washed by adding cold 
(−20°C) methanol and centrifuging at the same conditions, while the lipid and metabolite 
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fractions were isolated and saved for future analyses. Protein pellets were then dried in a 
vacuum centrifuge and dissolved in 50 mM NH4HCO3 containing 8 M urea and 10 mM 
dithiothreitol. After incubating for 1 h at 37°C with shaking at 800 rpm, 400 mM 
iodoacetamide was added to a final concentration of 40 mM, and the mixture incubated for 
another h at the same conditions. The reaction mixture was then diluted 8 folds with 50 mM 
NH4HCO3, and 1 M CaCl2 was added to a final concentration of 1 mM. Proteins were 
digested for 5 h at 37°C using trypsin at 1:50 enzyme:protein ratio. Digested peptides were 
desalted by solid-phase extraction using C18 cartridges (Discovery, 50 mg, Sulpelco) and 
dried in a vacuum centrifuge. Peptides were then labeled and sorted into 2 sets of tandem 
mass tags (TMT-10plex, Thermo Fisher Scientific) following the manufacturer’s 
recommendations and desalted again using C18 cartridges. Labeled peptides were 
fractionated into 24 fractions using high-pH reversed phase chromatography, dried in a 
vacuum centrifuge and resuspended in 0.1% formic acid (Wang et al., 2011).
Peptides were analyzed on a Waters NanoAquity UPLC system with a custom packed C18 
column (70 cm × 75 μm i.d., Phenomenex Jupiter, 3 μm particle size, 300Å pore size) 
coupled with a Q-Exactive mass spectrometer (Thermo Fisher Scientific). Peptide separation 
was carried out with a gradient of water (solvent A) and acetonitrile (solvent B) both 
containing 0.1% formic acid (1%–8% B in 2 min, 8%–12% B in 18 min, 12%–30% B in 55 
min, 30%–45% B in 22 min, 45%–95% B in 3 min, hold for 5 min in 95% B and 99%–1% B 
in 10 min). Eluting peptides were directly analyzed by nanoelectrospray ionization and full-
MS scans were collected over 400–2000 m/z at a resolution of 35,000 at 400 m/z. The top 
12 most intense parent ions were submitted to high-energy collision induced dissociation 
(HCD) fragmentation (2.0 m/z isolation width; 30% normalized collision energy; 17,500 
resolution at 400 m/z), before being dynamically excluded for 30 s.
Tandem mass spectra were converted to DTA peak lists using Decon2LS_V2 (Mayampurath 
et al., 2008) combined with DTARefinery (Petyuk et al., 2010), both using default 
parameters. MSGF+ (Kim and Pevzner, 2014) was then used to search peptide spectra 
against islet protein sequences based on the RNAseq data from a previous study (Eizirik et 
al., 2012) deposited in RefSeq and supplemented with keratin sequences (32,780 total 
protein sequences). As searching parameters, the parent ion mass tolerance was set at 10 
ppm, tryptic digestion in at least one of the termini was considered, and 2 missed cleavages 
were allowed. Cysteine carbamidomethylation and N-terminal/lysine TMT addition were 
searched as static modifications, whereas methionine oxidation was set as variable 
modification. Spectral-peptide matches were first filtered using a MSGF probability ≤ 1.0E 
−9, and then further filtered at protein level with a probability ≤ 1.0E −10, resulting in < 1% 
false-discovery rate.
Label-free Proteomic Analysis—Approximately 150 treated or control islets from 2 
independent donors were obtained from IIDP as described above, and digested with trypsin 
using trifluoroethanol as a denaturing agent (Wang et al., 2005). Peptides were fractionated 
into 12 fractions by high resolution reversed phase capillary liquid chromatography 
employing a nanoACQUITY UPLC® system (Waters Corporation, Milford, MA) equipped 
with an autosampler. Capillary columns, 200 μm i.d. × 50 cm long, were packed with 3 μm 
Jupiter C18 bonded particles (Phenomenex, Torrence, CA). Separations were performed at a 
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flow rate of 3.3 μL/min using a binary pump system, with 10 mM ammonium formate (pH 
10.0) as mobile phase A and 10 mM ammonium formate in 90% acetonitrile (pH 10.0) as 
mobile phase B. 45 μL of peptide mixtures (0.5 μg/μL) were loaded onto the column and 
separated using a binary gradient of 5%–15% B in 15 min, 15%–25% B in 25 min, 25%–
45% B in 25 min, and 45%–90% B in 38 min. The eluate was collected in 96 fractions and 
further concatenated into 12 samples, which were then individually analyzed by LC-MS/MS 
as described above. The data were processed with MaxQuant v.1.5.3.28 (Tyanova et al., 
2016) by searching against the protein sequence database described above, and considering 
trypsin digestion specificity in at least one of the peptide termini, methionine oxidation as 
variable modification and cysteine carbamidomethylation as fixed modification. The ion 
mass tolerance was set at 20 and 4.5 ppm for the first and main peptide searches. The data 
were filtered at 1% false-discovery rate in both peptide-spectrum matches and protein levels. 
Then the quantification was performed by label-free quantification using default parameters.
Western Blotting—After cytokine treatment the human islets, EndoC-βH1 cells and 
MIN6 cells were harvested and lysed with lysis buffer and protein content was determined 
using the Lowry method. A total of 20 μg of protein per sample was electrophoresed on 4%–
20% Bis-Tris gels (Bio-Rad) under denaturing conditions and blotted onto a PVDF 
membrane. The blots were blocked and probed for the following primary antibodies with 
overnight incubation at 4°C: cleaved caspase 3 (Cell Signaling; 1:1000), Caspase 3 (1:1000), 
GDF15 (Bioss; 1:500), SPP1 (Thermo Fisher Scientific; 1:1000), b-tubulin (Cell Signaling; 
1:2000). Li-Cor anti-rabbit or anti-mouse (1:10000) secondary antibodies were used for the 
quantification of protein expression. The data were quantified using ImageStudio (LI-COR).
Caspase 3/7 Activity and Flow Cytometry Assay to Measure Apoptosis—
Caspase-Glo 3/7 assay kit (Promega) was used to analyze caspase activity. Briefly, human 
islets were pre-exposed to 100 ng/mL rGDF15 or 50 ng/mL rSPP1 for 24 h and treated or 
not with 50 U/mL IL-1β and 1000 U/mL IFN-γ for additional 24 h. After the treatment 
period 25 islets per well with similar size were handpicked and suspended in 1:1 ratio of 
culture media to caspase-Glo reagent (100 μL of media + 100 μL of caspase-Glo reagent) in 
a 96 well plate and incubated for 1 h. The samples were read in a luminescent plate reader 
and the values were represented as relative luminescence units (RLU) of caspase 3/7 activity. 
We also measured cell viability by flow cytometry (BD, FACSCantoII) using the apoptotic 
(annexin V) and viability (7AAD) (BD Annexin A5 FITC/7-AAD Kit) markers. Briefly, 
human islets were dissociated by incubating them with 1mL of Accutase (edmillipore) and 
1ul of DNase I (edmillipore) at 37°C for 10 min. After 10 min of incubation, 0.1% of BSA-
PBS was added to stop the reaction and the cells were then washed twice with PBS and 
cultured overnight with islet culture media. After overnight culture the islets were 
replenished with fresh culture media and treated with or without rGDF15 and rSPP1 as 
mentioned above. On the day of measurement, the cells were washed twice with 0.1% BSA-
PBS and incubated for 20 min at 37°C in KRBS buffer supplemented with 3.3 mM D-
glucose and annexin V-FITC and 7-AAD and then analyzed using BD FACSCantoII.
Quantitative RT-PCR—Total RNA was isolated using RNeasy plus mini kit (QIAGEN) as 
per the manufacturer’s protocol. Reverse transcription was performed using M-MLV RT kit 
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(Invitrogen) and qRT-PCR was performed using TaqMan probe-based approach (Applied 
Biosystems). TaqMan primer were used for the quantification GDF15 and SPP1 messenger 
RNA expression and b-actin was used as a house-keeping control for the normalization and 
the data were expressed as relative fold expression against untreated control samples.
Polyribosomal Profiling—Polyribosomal profiling studies were performed using 
untreated and IL-1β + IFN-γ treated human EndoC-βH1 cells. Briefly, cells were lysed and 
centrifuged on a 10%–50% sucrose gradient. BioComp piston gradient fractionator 
connected with an in-line UV monitor (absorbance 254 nm) was used to determine the RNA 
and gradients were collected in ten 1mL fractions. Fractions from 1 to 5 were considered to 
be monoribosome-associated RNAs and fractions 6 to 10 were considered to be 
polyribosome-associated RNAs. PM ratio (polysomes to monosomes ratio) was calculated 
by area under the curve (AUC) of polysome fractions (more than two ribosomes) divided by 
area under the curve of monosome fractions (80S ribosome). Percentage of mRNA 
expression was calculated as described previously (Templin et al., 2014). P/M ratio for 
GDF15 mRNA was calculated by using total percentage of 6 to 10 polysome fractions 
divided by total percentage of 1 to 5 monosome fractions.
Animal Studies—For the insulitis study, NOD mice (n = 5) were acclimatized for one 
week and were then injected intraperitoneally every second day for two weeks with 0.5 
mg/kg rGDF15 dissolved in water or water alone. Recombinant proteins were previously 
tested for TGF-β contamination by ELISA, confirming absence of TGF-β in the 
preparations. For the diabetes prevention study, we used 20 mice per group, which in 
previous studies from our group (Cabrera et al., 2013), was shown to provide a 95% power 
to detect an increase in non-diabetic proportion of 0.66 with a significance level (alpha) of 
0.05 (two-tailed). NOD mice were acclimatized for one week and then beginning at 6 weeks 
of age were injected intraperitoneally (IP) every 2 days for 4 weeks with 0.5 mg/kg rGDF15 
dissolved in saline or saline alone. Mice were monitored for 24 weeks, until > 80% of the 
control group developed diabetes (blood glucose level > 250 mg/mL on two separate 
occasions. Body weight and blood glucose were monitored as previously described (Maganti 
et al., 2016). Mice were euthanized and pancreata were harvested at the end of the different 
experiments.
Immunohistochemistry/Immunofluorescence—Pancreata were fixed with 4% PFA 
at room temperature for 4 h, paraffin embedded, and immunostaining was performed as 
previously described (Evans-Molina et al., 2009) using the following antibodies: insulin 
(Santa Cruz) and counter stained with peroxidase conjugated anti-rabbit IgG (Vector). 
Insulitis was scored from immunohistochemical staining as described previously (Tersey et 
al., 2014) using at least 3 pancreas sections 70 μm apart from 5 mice per group and the 
images were acquired using an EVOIS XL Core microscope (Life Technologies). For studies 
using immunofluorescence we used the following primary antibodies: insulin (Dako; 1:400), 
GDF15 (Bioss; 1:200), SPP1 (Thermo Fisher Scientific; 1:200), 4-HNE (Abcam; 1:200), 
glucagon (Abcam; 1:300) and counter stained with following secondary antibodies: goat 
anti-guinea pig (Alexa 488; 1:400), donkey anti-rabbit (Alexa-568; 1:250) and donkey anti-
mouse (Alexa-647; 1:300). The images were acquired using LSM 800 confocal microscope 
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(Carl Ziess, Germany). Experiments without the primary antibody and with a competition 
assay by adding recombinant protein were run in parallel to assess the specificity of the 
staining.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantitative and Pathway Analysis of TMT-labeled Proteomic Analysis—For 
quantification, TMT reporter ion intensities of confidently identified peptides were extracted 
with MASIC (Monroe et al., 2008). Then intensities of reporter ions of peptides with 
multiple MS/MS spectra were summed together to remove redundancy and increase signal-
to-noise ratios. Quality control processing of the proteomics data include sample-level 
outlier evaluation using a robust Principal Component Analysis (Webb-Robertson et al., 
2011) and total sample abundance normalization with median centering (Callister et al., 
2006; Webb-Robertson et al., 2011). No sample-level issues were identified. Proteins were 
quantified with a standard reference-based quantification (Taverner et al., 2012; Wang et al., 
2013). The Bioconductor analysis package limma (Ritchie et al., 2015) was used to identify 
proteins differentially expressed in each of the two TMT sets, using the paired samples 
setting. Statistical power was calculated based on a two-sided paired t test with a type one 
error rate, a, of 0.05 using the ‘sampsizepwr’ function in MATLAB R2018a. The standard 
deviation was computed for each protein from the control group for both set 1 and set 2, 
10,621 and 11,404 proteins, respectively. Normality of the proteomics data was evaluated 
with a Kolmogrov-Smirnov test of normality and in all cases less than 5% failed to meet our 
assumptions of normality.
The DAVID online resource (http://david.ncifcrf.gov) was then used to obtain functional 
enrichment of up- and downregulated proteins. Only enriched functions from KEGG 
database was used for plotting the pathway network with Enrichment Map tool (Merico et 
al., 2010). Physical/regulatory interactions among differentially abundant apoptotic proteins 
were mapped with Metacore pathway analysis software (Thomson Reuters) using the gene 
ontology process “regulation of apoptotic processes.”
Image Processing and Quantification—For quantification of immunofluorescence 
experiments, human pancreatic sections were examined by acquiring Z stacks images using 
confocal microscopy (Carl Zeiss Microscopy, Germany). Fluorescence intensity of the 
images was quantified by using ImageJ (NIH) as described elsewhere (Sun et al., 2016). 
Briefly, from each pancreatic section, 5–10 islets were randomly selected, and the islet areas 
(number of pixels) and their integrated densities were then measured. Background 
fluorescence intensity was measured for each islet and the corrected total islet cell 
fluorescence was calculated by the following formula: Total Islet Cell Fluorescence (CTCF) 
= Integrated Density - (Area of selected cell X Mean fluorescence of background). All 
image analyses were performed in a blinded fashion and independently by two individuals.
Statistical Analysis of Other Experiments—Besides the proteomic analysis, statistical 
test of all the other experiments were performed with GraphPad Prism (GraphPad Software). 
For most of the experiments, results were considered significant when p ≤ 0.05 for Student’s 
t test (two-tailed, unpaired). For the proteomics versus transcriptomics comparison a two-
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tailed Fisher’s exact was used and considered significant with p ≤ 0.05 cutoff. For the image 
quantitative analysis, an one-way ANOVA test was used and considered significant with p ≤ 
0.05. For NOD mouse diabetes outcome experiments, a log-rank (Mantel-Cox) test was used 
to determine significance between control- and rhGDF15-treated groups. Normality of data 
was evaluated with a Kolmogrov-Smirnov test of normality and in all cases less than 5% 
failed to meet our assumptions of normality.
For all statistical analyses, the parameters can be found in the figures and figure legends, as 
applicable.
DATA AND CODE AVAILABILITY
The raw LC-MS/MS proteomics data files were deposited in the ProteomeXchange-
associated Pride data repository under the accession number PXD009131.
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Refer to Web version on PubMed Central for supplementary material.
ACKNOWLEDGMENTS
The authors thank Nathan Johnson and Rose Perry for their help with the illustrations. The authors thank the 
NIDDK-supported Integrated Islet Distribution Program (IIDP) and Network for Pancreatic Organ Donors with 
Diabetes (nPOD) for providing the human islets and pancreas tissue sections, respectively, used in the study. This 
work was supported by National Institutes of Health (NIH), United States, National Institute of Diabetes and 
Digestive and Kidney Diseases grants UC4 DK104166 (to R.G.M, C.E.M., D.L.E., and T.O.M.), UC4 DK104167 
(W.J.Q. and R.N.K.), UC4 DK108101, R01 DK60581 (to R.G.M.), and R01 DK093954 (to C.E.M); United States 
Department of Veterans Affairs, VA Merit Award I01BX001733 (to C.E.M.); Fonds National de la Recherche 
Scientifique (FNRS), Welbio CR-2015A-06, Belgium (to D.L.E.); a JDRF (United States) Strategic Research 
Agreement (to C.E.M and R.G.M.); and gifts from the Sigma Beta Sorority (United States), the Ball Brothers 
Foundation (United States), the George and Frances Ball Foundation (United States), and the Holiday Management 
Foundation (United States) (to C.E.M and R.G.M.). F.S. was supported by JDRF postdoctoral fellowship (3-
PDF-2016-199-A-N). D.L.E. also received funds from Innovative Medicines Initiative 2 Joint Undertaking under 
grant agreement no. 115797 (INNODIA), which is supported by the Union’s Horizon 2020 research and innovation 
program and EFPIA (Belgium), JDRF and The Leona M. and Harry B. Helmsley Charitable Trust (United States). 
This work used core services supported by NIH grant P30 DK097512 (to Indiana University) and by NIH grant P30 
DK020595 (to University of Chicago). Work was performed in the Environmental Molecular Sciences Laboratory, a 
U.S. Department of Energy (DOE) national scientific user facility at Pacific Northwest National Laboratory 
(PNNL) in Richland, WA. Battelle operates PNNL for the DOE under contract DE-AC05-76RLO01830.
REFERENCES
Anderson MS, and Bluestone JA (2005). The NOD mouse: a model of immune dysregulation. Annu. 
Rev. Immunol 23, 447–485. [PubMed: 15771578] 
Artz A, Butz S, and Vestweber D (2016). GDF-15 inhibits integrin activation and mouse neutrophil 
recruitment through the ALK-5/TGF-βRII heterodimer. Blood 128, 529–541. [PubMed: 27235139] 
Atkinson MA, Eisenbarth GS, and Michels AW (2014). Type 1 diabetes. Lancet 383, 69–82. [PubMed: 
23890997] 
Bi X, Li F, Liu S, Jin Y, Zhang X, Yang T, Dai Y, Li X, and Zhao AZ (2017). ω−3 polyunsaturated 
fatty acids ameliorate type 1 diabetes and autoimmunity. J. Clin. Invest 127, 1757–1771. [PubMed: 
28375156] 
Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, 
Mahler S, Pryor K, et al. (1997). MIC-1, a novel macrophage inhibitory cytokine, is a divergent 
member of the TGF-beta superfamily. Proc. Natl. Acad. Sci. USA 94, 11514–11519. [PubMed: 
9326641] 
Nakayasu et al. Page 17













Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, and von Herrath M (2006). Anti-
CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune 
diabetes by inducing Tregs. J. Clin. Invest 116, 1371–1381. [PubMed: 16628253] 
Brissova M, Niland JC, Cravens J, Olack B, Sowinski J, and Evans-Molina C (2019). The integrated 
islet distribution program answers the call for improved human islet phenotyping and reporting of 
human islet characteristics in research articles. Diabetes 68, 1363–1365. [PubMed: 31092479] 
Brooks SA, and Blackshear PJ (2013). Tristetraprolin (TTP): interactions with mRNA and proteins, 
and current thoughts on mechanisms of action. Biochim. Biophys. Acta 1829, 666–679. [PubMed: 
23428348] 
Cabrera SM, Colvin SC, Tersey SA, Maier B, Nadler JL, and Mirmira RG (2013). Effects of 
combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-
obese diabetic mouse model of type 1 diabetes. Clin. Exp. Immunol 172, 375–382. [PubMed: 
23600825] 
Cai M, Bompada P, Salehi A, Acosta JR, Prasad RB, Atac D, Laakso M, Groop L, and De Marinis Y 
(2018). Role of osteopontin and its regulation in pancreatic islet. Biochem. Biophys. Res. 
Commun 495, 1426–1431. [PubMed: 29180017] 
Callister SJ, Barry RC, Adkins JN, Johnson ET, Qian WJ, Webb-Robertson BJ, Smith RD, and Lipton 
MS (2006). Normalization approaches for removing systematic biases associated with mass 
spectrometry and label-free proteomics. J. Proteome Res 5, 277–286. [PubMed: 16457593] 
Campbell-Thompson M, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, and Atkinson MA 
(2016). Insulitis and β-cell mass in the natural history of type 1 diabetes. Diabetes 65, 719–731. 
[PubMed: 26581594] 
Carpenter S, Ricci EP, Mercier BC, Moore MJ, and Fitzgerald KA (2014). Post-transcriptional 
regulation of gene expression in innate immunity. Nat. Rev. Immunol 14, 361–376. [PubMed: 
24854588] 
Carstensen M, Herder C, Brunner EJ, Strassburger K, Tabak AG, Roden M, and Witte DR (2010). 
Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but 
is not an independent predictor of type 2 diabetes: the Whitehall II study. Eur. J. Endocrinol 162, 
913–917. [PubMed: 20167682] 
Chung HK, Ryu D, Kim KS, Chang JY, Kim YK, Yi HS, Kang SG, Choi MJ, Lee SE, Jung SB, et al. 
(2017). Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. 
J. Cell Biol 216, 149–165. [PubMed: 27986797] 
Clemente N, Raineri D, Cappellano G, Boggio E, Favero F, Soluri MF, Dianzani C, Comi C, Dianzani 
U, and Chiocchetti A (2016). Osteopontin bridging innate and adaptive immunity in autoimmune 
diseases. J. Immunol. Res 2016, 7675437. [PubMed: 28097158] 
Cunha DA, Cito M, Grieco FA, Cosentino C, Danilova T, Ladrière L, Lindahl M, Domanskyi A, 
Bugliani M, Marchetti P, et al. (2017). Pancreatic β-cell protection from inflammatory stress by the 
endoplasmic reticulum proteins thrombospondin 1 and mesencephalic astrocyte-derived 
neutrotrophic factor (MANF). J. Biol. Chem 292, 14977–14988. [PubMed: 28698383] 
DiMeglio LA, Evans-Molina C, and Oram RA (2018). Type 1 diabetes. Lancet 391, 2449–2462. 
[PubMed: 29916386] 
Ehlers MR (2016). Immune interventions to preserve β cell function in type 1 diabetes. J. Investig. 
Med 64, 7–13.
Eizirik DL, Colli ML, and Ortis F (2009). The role of inflammation in insulitis and beta-cell loss in 
type 1 diabetes. Nat. Rev. Endocrinol 5, 219–226. [PubMed: 19352320] 
Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, Igoillo-Esteve M, Ortis F, Santin I, Colli 
ML, Barthson J, et al. (2012). The human pancreatic islet transcriptome: expression of candidate 
genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 8, e1002552. 
[PubMed: 22412385] 
Eizirik DL, Miani M, and Cardozo AK (2013). Signalling danger: endoplasmic reticulum stress and 
the unfolded protein response in pancreatic islet inflammation. Diabetologia 56, 234–241. 
[PubMed: 23132339] 
Elenkov IJ, and Chrousos GP (2002). Stress hormones, proinflammatory and antiinflammatory 
cytokines, and autoimmunity. Ann. N Y Acad. Sci 966, 290–303. [PubMed: 12114286] 
Nakayasu et al. Page 18













Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Sindelar DK, 
Ballman KK, et al. (2017). The metabolic effects of GDF15 are mediated by the orphan receptor 
GFRAL. Nat. Med 23, 1215–1219. [PubMed: 28846098] 
Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, 
Deering TG, Keller SR, Maier B, and Mirmira RG (2009). Peroxisome proliferator-activated 
receptor gamma activation restores islet function in diabetic mice through reduction of 
endoplasmic reticulum stress and maintenance of euchromatin structure. Mol. Cell. Biol 29, 2053–
2067. [PubMed: 19237535] 
Gonzalez-Duque S, Azoury ME, Colli ML, Afonso G, Turatsinze JV, Nigi L, Lalanne AI, Sebastiani 
G, Carre A, Pinto S, et al. (2018). Cell Metab. 28, 946–960.e6. [PubMed: 30078552] 
Guney MA, Petersen CP, Boustani A, Duncan MR, Gunasekaran U, Menon R, Warfield C, Grotendorst 
GR, Means AL, Economides AN, and Gannon M (2011). Connective tissue growth factor acts 
within both endothelial cells and beta cells to promote proliferation of developing beta cells. Proc. 
Natl. Acad. Sci. USA 108, 15242–15247. [PubMed: 21876171] 
Gupta S, Cerosaletti K, and Long SA (2014). Renegade homeostatic cytokine responses in T1D: 
drivers of regulatory/effector T cell imbalance. Clin. Immunol 151, 146–154. [PubMed: 24576418] 
Gurgul-Convey E, Kaminski MT, and Lenzen S (2015). Physiological characterization of the human 
EndoC-βH1 β-cell line. Biochem. Biophys. Res. Commun 464, 13–19. [PubMed: 26028562] 
Gurgul-Convey E, Mehmeti I, Plötz T, Jörns A, and Lenzen S (2016). Sensitivity profile of the human 
EndoC-βH1 beta cell line to proinflammatory cytokines. Diabetologia 59, 2125–2133. [PubMed: 
27460666] 
Gurzov EN, and Eizirik DL (2011). Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death 
and dysfunction. Trends Cell Biol. 21, 424–431. [PubMed: 21481590] 
Heger J, Schiegnitz E, von Waldthausen D, Anwar MM, Piper HM, and Euler G (2010). Growth 
differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. J. Cell. 
Physiol 224, 120–126. [PubMed: 20232299] 
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, 
Krischer JP, Linsley PS, et al.; Type 1 Diabetes TrialNet Study Group (2019). An anti-CD3 
antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med 381, 603–613. 
[PubMed: 31180194] 
Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, Kutach A, Joo W, Gao Z, Fu D, et 
al. (2017). Non-homeostatic body weight regulation through a brainstem-restricted receptor for 
GDF15. Nature 550, 255–259. [PubMed: 28953886] 
Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, Kikuchi M, Yazaki Y, Miyazaki JI, 
and Oka Y (1993). Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism 
and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36, 1139–
1145. [PubMed: 8270128] 
Jung SB, Choi MJ, Ryu D, Yi HS, Lee SE, Chang JY, Chung HK, Kim YK, Kang SG, Lee JH, et al. 
(2018). Reduced oxidative capacity in macrophages results in systemic insulin resistance. Nat. 
Commun 9, 1551. [PubMed: 29674655] 
Kahles F, Findeisen HM, and Bruemmer D (2014). Osteopontin: A novel regulator at the cross roads of 
inflammation, obesity and diabetes. Mol. Metab 3, 384–393. [PubMed: 24944898] 
Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-
Klingebiel M, Napp LC, Hansen B, et al. (2011). GDF-15 is an inhibitor of leukocyte integrin 
activation required for survival after myocardial infarction in mice. Nat. Med 17, 581–588. 
[PubMed: 21516086] 
Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, and Ng LL (2009). Growth 
differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur. 
Heart J 30, 1057–1065. [PubMed: 19168526] 
Kim S, and Pevzner PA (2014). MS-GF+ makes progress towards a universal database search tool for 
proteomics. Nat. Commun 5, 5277. [PubMed: 25358478] 
Krusche CA, Holthöfer B, Hofe V, van de Sandt AM, Eshkind L, Bockamp E, Merx MW, Kant S, 
Windoffer R, and Leube RE (2011). Desmoglein 2 mutant mice develop cardiac fibrosis and 
dilation. Basic Res. Cardiol 106, 617–633. [PubMed: 21455723] 
Nakayasu et al. Page 19













Lee SE, Kang SG, Choi MJ, Jung SB, Ryu MJ, Chung HK, Chang JY, Kim YK, Lee JH, Kim KS, et 
al. (2017). Growth differentiation factor 15 mediates systemic glucose regulatory action of T-
helper type 2 cytokines. Diabetes 66, 2774–2788. [PubMed: 28874416] 
Li J, Yang L, Qin W, Zhang G, Yuan J, and Wang F (2013). Adaptive induction of growth 
differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus. 
PLoS One 8, e65549. [PubMed: 23799024] 
Livingstone SJ, Levin D, Looker HC, Lindsay RS, Wild SH, Joss N, Leese G, Leslie P, McCrimmon 
RJ, Metcalfe W, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal 
Registry (2015). Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. 
JAMA 313, 37–44. [PubMed: 25562264] 
Luan HH, Wang A, Hilliard BK, Carvalho F, Rosen CE, Ahasic AM, Herzog EL, Kang I, Pisani MA, 
Yu S, et al. (2019). GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell 
178, 1231–1244.e11. [PubMed: 31402172] 
Lyssenko V, Eliasson L, Kotova O, Pilgaard K, Wierup N, Salehi A, Wendt A, Jonsson A, De Marinis 
YZ, Berglund LM, et al. (2011). Pleiotropic effects of GIP on islet function involve osteopontin. 
Diabetes 60, 2424–2433. [PubMed: 21810601] 
Maganti AV, Tersey SA, Syed F, Nelson JB, Colvin SC, Maier B, and Mirmira RG (2016). Peroxisome 
proliferator-activated receptor-g activation augments the β-cell unfolded protein response and 
rescues early glycemic deterioration and β cell death in non-obese diabetic mice. J. Biol. Chem 
291, 22524–22533. [PubMed: 27613867] 
Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, and Tochino Y (1980). Breeding of a 
non-obese, diabetic strain of mice. Jikken Dobutsu 29, 1–13. [PubMed: 6995140] 
Mayampurath AM, Jaitly N, Purvine SO, Monroe ME, Auberry KJ, Adkins JN, and Smith RD (2008). 
DeconMSn: a software tool for accurate parent ion monoisotopic mass determination for tandem 
mass spectra. Bioinformatics 24, 1021–1023. [PubMed: 18304935] 
Merico D, Isserlin R, Stueker O, Emili A, and Bader GD (2010). Enrichment map: a network-based 
method for gene-set enrichment visualization and interpretation. PLoS One 5, e13984. [PubMed: 
21085593] 
Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y, Oka Y, and Yamamura K (1990). 
Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special 
reference to expression of glucose transporter isoforms. Endocrinology 127, 126–132. [PubMed: 
2163307] 
Monroe ME, Shaw JL, Daly DS, Adkins JN, and Smith RD (2008). MASIC: a software program for 
fast quantitation and flexible visualization of chromatographic profiles from detected LC-
MS(/MS) features. Comput. Biol. Chem 32, 215–217. [PubMed: 18440872] 
Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, 
Dinh TQ, Cash-Mason TD, et al. (2017). GFRAL is the receptor for GDF15 and the ligand 
promotes weight loss in mice and nonhuman primates. Nat. Med 23, 1150–1157. [PubMed: 
28846097] 
Nakayasu ES, Nicora CD, Sims AC, Burnum-Johnson KE, Kim YM, Kyle JE, Matzke MM, Shukla 
AK, Chu RK, Schepmoes AA, et al. (2016). MPLEx: a robust and universal protocol for single-
sample integrative proteomic, metabolomic, and lipidomic analyses. mSystems 1, e00043–16. 
[PubMed: 27822525] 
Ow SY, Salim M, Noirel J, Evans C, Rehman I, and Wright PC (2009). iTRAQ underestimation in 
simple and complex mixtures: “the good, the bad and the ugly”. J. Proteome Res 8, 5347–5355. 
[PubMed: 19754192] 
Patel S, Alvarez-Guaita A, Melvin A, Rimmington D, Dattilo A, Miedzybrodzka EL, Cimino I, Maurin 
AC, Roberts GP, Meek CL, et al. (2019). GDF15 provides an endocrine signal of nutritional stress 
in mice and humans. Cell Metab. 29, 707–718.e8. [PubMed: 30639358] 
Petyuk VA, Mayampurath AM, Monroe ME, Polpitiya AD, Purvine SO, Anderson GA, Camp DG 
2nd, and Smith RD (2010). DtaRefinery, a software tool for elimination of systematic errors from 
parent ion mass measurements in tandem mass spectra data sets. Mol. Cell. Proteomics 9, 486–
496. [PubMed: 20019053] 
Nakayasu et al. Page 20













Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, Rowe P, Moraski JM, Ball S, 
Jebson L, et al. (2014). The juvenile diabetes research foundation network for pancreatic organ 
donors with diabetes (nPOD) program: goals, operational model and emerging findings. Pediatr. 
Diabetes 15, 1–9.
Ramos-Rodríguez M, Raurell-Vila H, Colli ML, Alvelos MI, Subirana-Granés M, Juan-Mateu J, 
Norris R, Turatsinze JV, Nakayasu ES, Webb-Robertson BM, et al. (2019). The impact of 
proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of 
type 1 diabetes. Nat. Genet 51, 1588–1595. [PubMed: 31676868] 
Ravassard P, Hazhouz Y, Pechberty S, Bricout-Neveu E, Armanet M, Czernichow P, and Scharfmann R 
(2011). A genetically engineered human pancreatic β cell line exhibiting glucose-inducible insulin 
secretion. J. Clin. Invest 121, 3589–3597. [PubMed: 21865645] 
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, and Smyth GK (2015). limma powers 
differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 
43, e47. [PubMed: 25605792] 
Santin I, Moore F, Colli ML, Gurzov EN, Marselli L, Marchetti P, and Eizirik DL (2011). PTPN2, a 
candidate gene for type 1 diabetes, modulates pancreatic β-cell apoptosis via regulation of the 
BH3-only protein Bim. Diabetes 60, 3279–3288. [PubMed: 21984578] 
Scharfmann R, Pechberty S, Hazhouz Y, von Bülow M, Bricout-Neveu E, Grenier-Godard M, Guez F, 
Rachdi L, Lohmann M, Czernichow P, and Ravassard P (2014). Development of a conditionally 
immortalized human pancreatic β cell line. J. Clin. Invest 124, 2087–2098. [PubMed: 24667639] 
Schiegnitz E, Kämmerer PW, Koch FP, Krüger M, Berres M, and Al-Nawas B (2012). GDF 15 as an 
anti-apoptotic, diagnostic and prognostic marker in oral squamous cell carcinoma. Oral Oncol. 48, 
608–614. [PubMed: 22341306] 
Sedlyarov V, Fallmann J, Ebner F, Huemer J, Sneezum L, Ivin M, Kreiner K, Tanzer A, Vogl C, 
Hofacker I, and Kovarik P (2016). Tristetraprolin binding site atlas in the macrophage 
transcriptome reveals a switch for inflammation resolution. Mol. Syst. Biol 12, 868. [PubMed: 
27178967] 
Suk K, Kim S, Kim YH, Kim KA, Chang I, Yagita H, Shong M, and Lee MS (2001). IFN-gamma/
TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN 
regulatory factor-1 pathway in pancreatic beta cell death. J. Immunol 166, 4481–4489. [PubMed: 
11254704] 
Sun Y, Ikrar T, Davis MF, Gong N, Zheng X, Luo ZD, Lai C, Mei L, Holmes TC, Gandhi SP, and Xu 
X (2016). Neuregulin-1/ErbB4 signaling regulates visual cortical p/lasticity. Neuron 92, 160–173. 
[PubMed: 27641496] 
Syed I, Rubin de Celis MF, Mohan JF, Moraes-Vieira PM, Vijayakumar A, Nelson AT, Siegel D, 
Saghatelian A, Mathis D, and Kahn BB (2019). PAHSAs attenuate immune responses and promote 
β cell survival in autoimmune diabetic mice. J. Clin. Invest 129, 3717–3731. [PubMed: 31380811] 
Taverner T, Karpievitch YV, Polpitiya AD, Brown JN, Dabney AR, Anderson GA, and Smith RD 
(2012). DanteR: an extensible R-based tool for quantitative analysis of -omics data. Bioinformatics 
28, 2404–2406. [PubMed: 22815360] 
Templin AT, Maier B, Tersey SA, Hatanaka M, and Mirmira RG (2014). Maintenance of Pdx1 mRNA 
translation in islet b-cells during the unfolded protein response. Mol. Endocrinol 28, 1820–1830. 
[PubMed: 25251389] 
Tersey SA, Colvin SC, Maier B, and Mirmira RG (2014). Protective effects of polyamine depletion in 
mouse models of type 1 diabetes: implications for therapy. Amino Acids 46, 633–642. [PubMed: 
23846959] 
Tiedje C, Diaz-Muñoz MD, Trulley P, Ahlfors H, Laaß K, Blackshear PJ, Turner M, and Gaestel M 
(2016). The RNA-binding protein TTP is a global post-transcriptional regulator of feedback 
control in inflammation. Nucleic Acids Res. 44, 7418–7440. [PubMed: 27220464] 
Tsai VW, Lin S, Brown DA, Salis A, and Breit SN (2016). Anorexia-cachexia and obesity treatment 
may be two sides of the same coin: role of the TGF-β superfamily cytokine MIC-1/GDF15. Int. J. 
Obes 40, 193–197.
Tyanova S, Temu T, and Cox J (2016). The MaxQuant computational platform for mass spectrometry-
based shotgun proteomics. Nat. Protoc 11, 2301–2319. [PubMed: 27809316] 
Nakayasu et al. Page 21













Unsicker K, Spittau B, and Krieglstein K (2013). The multiple facets of the TGF-β family cytokine 
growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev. 
24, 373–384. [PubMed: 23787157] 
Wang H, Qian WJ, Mottaz HM, Clauss TR, Anderson DJ, Moore RJ, Camp DG 2nd, Khan AH, Sforza 
DM, Pallavicini M, et al. (2005). Development and evaluation of a micro- and nanoscale proteomic 
sample preparation method. J. Proteome Res 4, 2397–2403. [PubMed: 16335993] 
Wang Y, Yang F, Gritsenko MA, Wang Y, Clauss T, Liu T, Shen Y, Monroe ME, Lopez-Ferrer D, Reno 
T, et al. (2011). Reversed-phase chromatography with multiple fraction concatenation strategy for 
proteome profiling of human MCF10A cells. Proteomics 11, 2019–2026. [PubMed: 21500348] 
Wang J, Webb-Robertson BJ, Matzke MM, Varnum SM, Brown JN, Riensche RM, Adkins JN, Jacobs 
JM, Hoidal JR, Scholand MB, et al. (2013). A semiautomated framework for integrating expert 
knowledge into disease marker identification. Dis. Markers 35, 513–523. [PubMed: 24223463] 
Webb-Robertson BJ, Matzke MM, Jacobs JM, Pounds JG, and Waters KM (2011). A statistical 
selection strategy for normalization procedures in LC-MS proteomics experiments through 
dataset-dependent ranking of normalization scaling factors. Proteomics 11, 4736–4741. [PubMed: 
22038874] 
Whitson RJ, Lucia MS, and Lambert JR (2013). Growth differentiation factor-15 (GDF-15) suppresses 
in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2). J. 
Cell. Biochem 114, 1424–1433. [PubMed: 23280549] 
Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkjær SB, Wu X, Huang T, Hultman K, Paulsen SJ, et 
al. (2017). GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the 
ligand. Nat. Med 23, 1158–1166. [PubMed: 28846099] 
Yu J, Yin P, Yin J, Liu F, Zhu X, Cheng G, Guo K, Yin Y, and Xu J (2010). Involvement of ERK1/2 
signalling and growth-related molecules’ expression in response to heat stress-induced damage in 
rat jejunum and IEC-6 cells. Int. J. Hyperthermia 26, 538–555. [PubMed: 20707649] 
Nakayasu et al. Page 22














Type 1 diabetes results from the apoptotic destruction of the insulin-producing pancreatic 
β cells by an autoimmune response. Here, researchers at Pacific Northwest National 
Laboratory and their collaborators identified a protein, growth/differentiation factor 15 
(GDF15), as a β-cell protective factor. GDF15 blocked pro-inflammatory cytokine-
mediated cell death of human islets and a β-cell line. GDF15 also reduced the 
autoimmune response and diminished the onset of diabetes in mice. Therefore, GDF15 is 
a potential target for developing a therapy for type 1 diabetes.
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• Proteomics of cytokine-treated human islets identified GDF15 as a protective 
factor
• GDF15 levels were reduced in cytokine-treated islets by translational 
blockade
• GDF15 inhibited IL-1β +INF-γ-induced apoptosis of human islets and a β-
cell line
• Administration of GDF15 prevented diabetes in non-obese diabetic mice
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Figure 1. Global Proteomic Analysis of Human Pancreatic Islets Treated with IFN-γ and IL-1β 
Using Tandem Mass Tags
(A) Experimental workflow of the proteomic analysis of pancreatic islets.
(B) Number of identified proteins. The complete list of identified proteins is shown in Table 
S1.
(C) Heatmap of consistently significant proteins in both proteomic sets (see Table S2 for the 
complete list). The statistical power is shown in Figures S1A and S1B and a cross-validation 
set in Figures S1C–S1E.
(D) Function-enrichment analysis of the differentially abundant proteins upon IFN-γ and 
IL-1β treatment. The network was clustered according to similar functions of significantly 
enriched pathways. The intensity of red colors of the nodes represents how significant the 
enrichment is, while the thickness of the edges represents the degree of similarity (shared 
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proteins) between pathways. A detailed network of proteins related to apoptosis is shown in 
Figure S1F.
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Figure 2. Cytokines, Chemokines, and Growth Factors Regulated by IFN-γ and IL-1β in 
Pancreatic Islets
(A) Cytokines, chemokines, and growth factors significantly regulated by IFN-γ and IL-1β 
treatment of human islets.
(B) Western blot and quantification (right panels) of GDF15 and SPP1 in EndoC-βH1 cells 
treated with IL-1β and IFN-γ.
(C) Western blot of GDF15 and SPP1 in MIN6 cells treated with IL-1β and IFN-γ.
(D and E) Immunofluorescence analysis of SPP1 (D) and GDF15 (E) in pancreata derived 
from NOD mice with or without insulitis.
t test: *p ≤ 0.05, ***p ≤ 0.001.
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Figure 3. Growth/Differentiation Factor 15 (GDF15) Expression Is Post-transcriptionally 
Regulated in β Cells Treated with Cytokines
(A) GDF15 and SPP1 levels in human islets treated with the combination of cytokines IL-1β
+IFN-γ were measured by label-free proteomics, western blot, and qPCR. The western blot 
image is shown in Figure S2.
(B) Regulation of protein abundances by IL-1β+IFN-γ. All the 387 significantly regulated 
proteins were compared against their transcript levels from a previous publication (Eizirik et 
al., 2012). The graph shows proteins that had their mRNA and protein levels regulated in a 
synchronized or unsynchronized fashion.
(C) Polyribosomal profiling of GDF15 transcript in EndoC-βH1 cells treated with the 
combination of cytokines IL-1β+IFN-γ.
(D) Ratio of GDF15 transcript bound to poly over monoribosomes (P/M).
t test: *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001. Fisher’s exact test: # p ≤ 0.0001.
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Figure 4. Growth/Differentiation Factor 15 (GDF15) and Osteopontin (SPP1) Block Interferon 
(INF)-γ- and Interleukin (IL)-1β-Induced Apoptosis
(A) Network analysis using MetaCore of downstream signaling of GDF15 and SPP1. Note 
that both GDF15 and SPP1 regulate the apoptotic pathway by different but overlapping 
signaling.
(B) EndoC-βH1 human β cells pretreated with SPP1 and GDF15 and then stimulated with 
the cytokines INF-γ and IL-1β. Cell lysates were analyzed by western blot by probing with 
anti-cleaved (active) caspase 3, anti-caspase 3, and anti-β-tubulin (loading control) 
antibodies.
(C and D) Quantification of western blot bands from
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(B). Relative expression of cleaved caspase 3 in different samples compared to the untreated 
control sample (C). Relative expression of caspase 3 in different samples compared to the 
untreated control sample (D).
(E) Caspase 3/7 activity measured by luminescent enzymatic assay (expressed in relative 
luminescence units) in human islets pretreated with SPP1 and GDF15 and then stimulated 
with the cytokines INF-γ and IL-1β.
A cross-validation experiment by flow cytometry is shown in Figure S3. t test: *p ≤ 0.05, 
**p ≤ 0.01 and ***p ≤ 0.001.
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Figure 5. Growth/Differentiation Factor 15 (GDF15) Reduces Insulitis in NOD Mice
NOD mice (n = 5 per group) were injected intraperitoneally every second day for two weeks 
with 0.5 mg/kg recombinant GDF15 (rGDF15) and monitored for body weight, blood 
glucose, insulitis, and oxidative stress.
(A and B) Body weight (A) and blood glucose levels
(B) of mice treated with GDF15.
(C) Immunohistochemistry of pancreata from mice treated or not with GDF15.
(D) Degree of insulitis in control mice and mice treated with GDF15.
(E) Immunofluorescence staining of 4-hydroxynonenal (4HNE) of pancreata from mice 
treated or not with GDF15.
t test: *p ≤ 0.05.
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Figure 6. Effect of Growth/Differentiation Factor 15 (GDF15) on the Development of Diabetes in 
NOD Mice
NOD mice (n = 20 per group) were injected intraperitoneally every two days between 6 and 
12 weeks of age with 0.5 mg/kg recombinant human GDF15 (rhGDF15) and monitored for 
blood glucose until >80% of the control group developed diabetes (defined as glucose > 250 
mg/dL on two consecutive measurements). *Statistical analysis was performed using 
Mantel-Cox test.
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Figure 7. Expression of GDF15 in Human Pancreas
(A) Pancreas tissue sections from normoglycemic human donors and from those diagnosed 
with T1D and T2D were stained for DNA, insulin, glucagon, and GDF15. IDs represent 
donor identification numbers from the Network for Pancreatic Organ Donors with Diabetes 
(nPOD) (Table S4). Scale bars represent 20 μm.
(B) Quantification of staining intensities of insulin, glucagon, and GDF15.
ANOVA Test: *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-cleaved caspase 3 Cell Signaling Technology Cat# 9664; RRID:AB_2070042
Anti-caspase 3 Cell Signaling Technology Cat# 9662; RRID:AB_331439
Anti-GDF15 Bioss Cat# bs-3818R; RRID:AB_10857699
Anti-SPP1 Thermo Fisher Scientific Cat# PA5–34579; RRID:AB_2551931
Anti-Tubulin Cell Signaling Technology Cat# 2128; RRID:AB_823664
Anti-rabbit IgG Li-Cor Biosciences Cat# 926–68073; RRID:AB_10954442
Anti-mouse IgG Li-Cor Biosciences Cat# 926–32212; RRID:AB_621847
Anti-insulin Santa Cruz Biotechnology Cat# sc-9168; RRID:AB_2126540
peroxidase conjugated anti-rabbit IgG Vector Labs Cat# MP-7401; RRID:AB_2336529
Anti-Glucagon Abcam Cat# ab10988; RRID:AB_297642
Anti-insulin Agilent Cat# A0564; RRID:AB_10013624
Anti-4-HNE Abcam Cat# ab46545; RRID:AB_722490
goat anti-guinea pig (Alexa Fluor-488) Molecular Probes Cat# A-11073; RRID:AB_2534117
donkey anti-rabbit (Alexa Fluor-568) Thermo Fisher Scientific Cat# A10042; RRID:AB_2534017
donkey anti-mouse(Alexa Fluor-647) Thermo Fisher Scientific Cat# A-21240, RRID:AB_2535809
donkey anti-rabbit (IRD®800CW) LI-COR Biosciences Cat# 926–32213; RRID:AB_621848
Chemicals, Peptides, and Recombinant Proteins
Ciprofloxacin Fisher MT61277RG
Penicillin Streptomycin Life Technologies Ltd 15140–122
Standard Islet Medium Prodo PIM-S001GMP
human AB serum Prodo PIM-ABS001GMP
Glutamine and Glutathione Supplement Prodo PIM-G001GMP
Dulbecco’s Modified Eagle Medium Life Technologies Ltd 11965–092
Dulbecco’s Modified Eagle Medium Life Technologies Ltd 11885–084
ECM Sigma-Aldrich E1270
Fibronectin from bovine plasma Sigma-Aldrich F1141
Nicotinamide Sigma-Aldrich N0636–100G
Sodium selenite Sigma-Aldrich S8132
Human Transferrin Sigma-Aldrich T8158
Fatty Acid Free heat shock BSA powder Equitech BAH66
Beta-2-mercaptoethanol Fisher BioReagents O3446I-100
Recombinant IL-1β R and D systems 201-LB-005
Recombinant IFN-γ R and D systems 285-IF-100
Recombinant SPP1 GenTex GTX48134-PRO
Halt phosphatase inhibitor cocktail Thermo Fisher Scientific 78420
Sodium fluoride Sigma S7920
Urea Sigma U0631
Ammonium Bicarbonate Sigma 9830
Calcium chloride Sigma C1016
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REAGENT or RESOURCE SOURCE IDENTIFIER
Tandem mass tags - 10plex Thermo Fisher Scientific 90110
Dithiothreitol Thermo Fisher Scientific 20291
Iodoacetamide Thermo Fisher Scientific 90034
Ammonium Formate Sigma 9735
Formic acid Sigma 33015
C18 SPE cartrigde, Discovery, 50 mg Supelco 52601-U
D-Sucrose Fisher Bio Reagent BP220–212
Cycloheximide solution Sigma C4859–1ML
Recombinant RNasin® Ribonuclease Inhibitor Promega N2515
Benzonase ® Nuclease Edmillipore 70746–3
Human GDF15 Protein (His Tag) – Produced in 
yeast; the absence of TGF-β contamination was 
confirmed by ELISA (R&D system; Cat#MB100B).
Sino Biologicals 10936-H07Y
Human GDF15 Protein – Produced in E. coli, 
endotoxin tested: < 1 EU/μg protein by LAL assay; 
the absence of TGF-β contamination was confirmed 
by ELISA (R&D system; Cat#MB100B).
ProSpec cyt-335
Annexin A5 FITC / 7-AAD Kit Beckman Coulter IM36154
Mini-PROTEAN TGX Gels BIO-RAD 456–1094
10X- Tris/Glycine/SDS Buffer BIO-RAD 161–0772
10X- Tris/Glycine Buffer BIO-RAD 161–0771
Signal Enhancer HIKARI 250 (Solution 1 & Solution 
2) Nacalai U.S.A NU00102
Critical Commercial Assays
Caspase-Glo 3/7 assay kit Promega G8090
RNeasy plus mini kit QIAGEN 74134
M-MLV RT kit Invitrogen 28025013
TaqMan Gene Expression Master mix Applied biosystems 4369016
Apo-ONE ® Homogeneous Caspase-3/7 Assay Promega G7790
Deposited Data
Proteomics data Pride repository PXD009131
Experimental Models: Cell Lines and Tissue
Human: EndoC-βH1 cells Dr. R. Scharfman (University of Paris, France) N/A
Mouse: MIN6 J. Miyazaki (Japan) N/A
Human: pancreatic islets Integrated Islet Distribution Program (IIDP) N/A
Human: pancreas tissue sections Network for Pancreatic Organ Donors with Diabetes (nPOD) N/A
Experimental Models: Organisms/Strains
Mouse: NOD/ShiLTJ (NOD) Jackson Laboratories 1976
Oligonucleotides
GDF15 TaqMan Cat# 4448892; ID Hs00171132_m1
SPP1 TaqMan Cat# 4331182; Hs00959010_m1
β-actin TaqMan Cat# 4333762F; ID Hs01060665_g1
Software and Algorithms
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REAGENT or RESOURCE SOURCE IDENTIFIER
MSGF+ Pevzner Lab, University of California - San Diego https://doi.org/10.1038/ncomms6277
MASIC Omics Group, Pacific Northwest National Laboratory
https://doi.org/10.1016/
j.compbiolchem.2008.02.006
Decon2LS_V2 Omics Group, Pacific Northwest National Laboratory https://doi.org/10.1186/1471-2105-10-87
DTARefinery Omics Group, Pacific Northwest National Laboratory
https://doi.org/10.1074/mcp.M900217-
MCP200
MaxQuant v.1.5.3.28 Cox Lab, Max-Planck Institute for Biochemistry https://doi.org/10.1038/nprot.2016.136
Enrichment Map Bader Lab, University of Toronto https://doi.org/10.1371/journal.pone.0013984
Metacore THOMSON REUTERS N/A
GraphPad Prism v7 GraphPad Software N/A
ImageJ software http://imagej.net/Contributors N/A
FCS Express v6 De Novo Software N/A
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